PTGES and systemic sclerosis: Our new data strongly suggest that, likely based on its essential role in driving inflammation, mPGES-1 may be considered a novel target that might be useful in slowing the initial, rapidly progressing, inflammatory phase of SSc that is required for the subsequent development of fibrosis and therefore may be useful in a stage-specific modulation of the pathogenesis of SSc.